Pharma major Lupin announced the launch of Silodosin Capsules 4mg and 8mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Silodosin Capsules 4mg and 8mg; is the generic equivalent of Allergan's Rapaflo. An alpha-1 adrenergic receptor antagonist, it is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Rapaflo had annual sales of USD 198.5 million in the US (IQVIA MAT September 2018).

Shares of the company declined Rs 10.35, or 1.17%, to trade at Rs 877.70. The total volume of shares traded was 26,434 at the BSE (9.47 a.m., Wednesday).